Preimplantation genetic diagnosis and the biopsy technique: Important considerations

Ermanno Greco, Gemma Fabozzi, Alessandra Ruberti, Daniela Zavaglia, Maria Giulia Minasi

Centre for Reproductive Medicine, European Hospital, Via Portuense, Rome, Italy; mg.minasi@gmail.com

Received 30 May 2013; revised 15 July 2013; accepted 23 July 2013

ABSTRACT

Preimplantation genetic diagnosis allows to test the genetic status of embryos prior to implantation. In order to obtain genetic material, on which carry out a genetic diagnosis, a procedure named embryo biopsy is required. In the last two decades, embryo biopsy at the cleavage stage has been the mostly performed procedure. However, recently, alternative methods allowing the retrieval of a larger number of cells (blastocyst stage biopsy), or representing a valid alternative to overcome ethical issues (polar body biopsy) have obtained increasing consensus. This article reviews different methods of embryo biopsy and points out their positive and negative aspects.

Keywords: Preimplantation Genetic Diagnosis; Screening; Polar Body; Embryo; Blastocyst Biopsy

1. INTRODUCTION

Preimplantation Genetic Diagnosis (PGD) has been conceived as an alternative to fetal prenatal diagnosis. Patients recurring to PGD are couples at risk of transmitting genetically inheritable disorders to their offspring. Most of them are fertile, but have been diagnosed with a specific genetic disease and this technique offers them the possibility to know the health status of their embryos before undertaking the pregnancy [1]. In many cases, they have a previous history of recurrent miscarriages of genetic origin or affected pregnancy terminations following invasive prenatal diagnosis procedure such as amniocentesis or chorionic villus sampling [2]. However, patients are usually advised to further perform prenatal diagnosis to confirm the status of the baby.

PGD diagnoses three main groups of inheritable disease: 1) monogenic disorders, which can affect autosomes or sex chromosomes with autosomal dominant, autosomal recessive, X-linked inheritance; 2) triplet repeat disorders, caused by an expansion of a triplet repeat of bases on a chromosome; 3) chromosome abnormalities, which can be numerical (aneuploidies) or structural (translocations or inversions) [1,2]. Additionally, PGD can be used to perform sex selection for non-medical reasons, [3,4] to detect mutations that can predispose to specific diseases (such as BRCA1 mutation which predispose to breast cancer) [5], to detect late-onset neurodegenerative disorders such as Huntington’s disease [5,6] and for HLA typing [7]. However, the ethical aspects concerning these indications remain controversial and are still under debate [5,8].

PGD technology has been recently used also to examine the genetic status in embryos from infertile couples undergoing IVF. In this case, the methodology is named Preimplantation Genetic Screening (PGS) or PGD for aneuploidy screening [9]. This procedure tests genetic conditions, in the absence of symptoms, with the aim to select “the chromosomally best embryo” for transfer [1]. It does not look for a specific disease; it just screens embryos for the most common genetic pathologies. Patients referred to PGS include couples with a history of repeated implantation failure in IVF, recurrent miscarriages and severe male factor infertility and advanced maternal age (AMA) [1,9,10]. However, different randomized control trials have demonstrated that PGS for AMA patients do not directly improves implantation or pregnancy rates [11-13].

The two main techniques used for genetic diagnosis are fluorescent in situ hybridization (FISH) for cytogenetic analysis of chromosomal abnormalities [14,15] and polymerase chain reaction (PCR) for molecular analysis of monogenic disorders [14,15] (Table 1). However, new methods of diagnosis requiring a whole-genome amplification (WGA) step to amplify a single cell DNA content prior to genetic analysis have been recently included in PGD/PGS clinical practice [16]. These techniques are array-comparative genomic hybridization (array-CGH) and single nucleotide polymorphism arrays (SNP-arrays).
Table 1. Main methods of genetic diagnosis.

<table>
<thead>
<tr>
<th>Method</th>
<th>Indications</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR</td>
<td>Monogenic disorders</td>
<td>Contamination (high risk)</td>
</tr>
<tr>
<td></td>
<td>Sexing</td>
<td>Allele drop-out</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Preferential amplification</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amplification failure</td>
</tr>
<tr>
<td>FISH</td>
<td>Chromosome abnormalities</td>
<td>Contamination (low risk)</td>
</tr>
<tr>
<td></td>
<td>Sexing</td>
<td>Mosaicism</td>
</tr>
<tr>
<td></td>
<td>Aneuploidy screening</td>
<td>Overlapping signals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Failure of probes binding</td>
</tr>
</tbody>
</table>

Table 2. Comparison between oocyte, embryo and blastocyst biopsy.

<table>
<thead>
<tr>
<th></th>
<th>Oocyte</th>
<th>Embryo</th>
<th>Blastocyst</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aneuploidy from first meiotic division</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Aneuploidy from second meiotic division</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Female translocations</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Male translocations</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cleavage mistakes</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Paternal contribution analyzed</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Absence of influence on embryo development</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>High DNA quantity</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less biopsies to be performed</td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Mosaicism effect reduced</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Embryo selection and Single Embryo Transfer</td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Absence of ethical problems</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In order to obtain genetic material on which carry out genetic diagnosis, both PGD and PGS require the procedure known as biopsy which consists in the removal of one or more cells from the embryo/oocyte to be diagnosed. Biopsy is performed using a micromanipulator equipment. Since this is an invasive procedure, the choice concerning the appropriate timing and methodology requires particular attention in order to ensure an uncompromised and correct development of the biopsied oocyte/embryo and to allow an accurate diagnosis.

2. BIOPSY

Biopsy can be performed at three different stages: on oocytes or zygotes (polar body biopsy), on 6 - 10 cells embryos (cleavage stage biopsy) or on blastocysts (blastocyst biopsy), (Table 2). Independently from the procedure chosen, a biopsy involves two steps: 1) zona pellucida (ZP) drilling, which can be performed mechanically, chemically or by laser energy [18-20], and 2) cell/s removal.

2.1. Polar Body Biopsy

Polar body biopsy consists in the removal of the first polar body (PB) from an oocyte in order to diagnose the genetic status before insemination. This procedure is referred as to Pre-Conception Genetic Diagnosis (PCGD) [21]. The first PB is extruded during Meiosis-I and it is not required to achieve a correct fertilization and/or embryo development, so its removal has not any detrimental effect on oocyte competence. First PB biopsy allows the evaluation of the genetic maternal contribution by the identification of chromosomal abnormalities [22-24] or gene mutations [15,25]. Additionally, it has been recently applied for HLA typing [26] and for the diagnosis of X-linked disorders [27].

The first use of PCGD was reported by Verlinsky and collaborators for cystic fibrosis screening on the first PB [28]. However, problems of misdiagnosis due to crossing-over events that can occur following fertilization, have shown that the second PB, which is extruded during fertilization, is often required for an accurate diagnosis [24].

Polar body biopsy is performed by aspiration for both first and second polar bodies. A hole in the ZP allows to access the perivitelline space, then a small beveled micropipette is used to gently aspirate the PB [29] (Figure 1). The timing of the procedure can differ according to indications. When only the first PB is required, aspiration is performed soon after oocyte retrieval, in order to avoid oocyte aging. When the second PB is required, aspiration can be performed simultaneously or sequentially. The sequential aspiration is performed by a two-step micromanipulation procedure: the first PB is removed soon after oocyte retrieval and the second after 6 - 14 hours post fertilization [30]. On the contrary, the simultaneous removal of first and second PBs can be performed in a less invasive single-step micromanipulation procedure, 6 - 14 hours post fertilization [29].

Important aspects to consider

Polar body biopsy is a valid alternative to embryo biopsy for those couples who have ethical objections to embryo biopsy or in Countries with legal restrictions on PGD, such as Germany and Italy. However, PCGD allows only to analyze the maternal contribution and therefore cannot be performed in case of disorders of male origin or for sexing [15]. Furthermore, the need of biopsing both first and second PBs, in some cases may represent a limit for this technique. In fact, PBs have a different morphology: the first one usually has a crinkly appearance while the second is smooth, but the distinction between them can be difficult. For this reason sequential aspiration is often preferred to the simultaneous...
one.

2.2. Cleavage Stage Biopsy

Embryonic blastomeres are totipotent and this property ensures that the removal of few cells (1 or 2) does not affect the ability of the remaining cells to differentiate in all the cell lineages required for a correct development. Hardy and colleagues were the first authors to report that blastomere removal does not affect further embryo competence [31].

This procedure is usually performed on day-3 post insemination, when embryos are at the 6 - 10 cells stage. If performed at earlier stages (4 cells), the ratio of inner cell mass (ICM) to trophectoderm cells (TE) may be altered, while, if performed at the stage of compaction, cell removal can be very difficult and may result in cell lysis since strong contacts among adjacent blastomeres have been established. The use of Ca²⁺/Mg²⁺ free media during embryo biopsy can be helpful to overcome this problem. When incubated in such media, membrane adhesions between blastomeres are loosen, lowering the risk of cell lysis during cell removal and shortening the duration of the whole procedure [32].

Different methods for blastomere removal have been developed and all of them require a hole in the zona in order to access the perivitelline space. The most widely used procedure is blastomere aspiration: a small beveled aspiration pipette is introduced into the perivitelline space and one or two blastomeres are gently aspirated (Figure 2). An alternative method is the extrusion technique which can be performed by the “stitch and pull” [33] or by “flow” displacement [34].

Important aspects to consider

A main advantage of cleavage stage biopsy is that once the embryo biopsy has been performed embryo cryopreservation is not necessary, avoiding the risk of embryo damage or death following the freezing/thawing process [35].

Biopsy on day three gives a sufficient time lapse period for cell genetic diagnosis since embryo transfers can be performed at blastocyst stage, after 2 or 3 days from

![Figure 1](image1.png)  ![Figure 2](image2.png)

Figure 1. Polar body biopsy. Oocyte is held with a holding pipette and the polar body is extracted with a biopsy pipette ((a)-(d)). In picture (e) is visible the polar body removed from the oocyte.

![Figure 1](image3.png)  ![Figure 2](image4.png)

Figure 2. Embryo biopsy. The embryo is held with a holding pipette and one blastomere is removed with a biopsy pipette ((a)-(g)). In picture (b) the hole in the zona pellucida performed with laser is visible (arrow). The blastomere immediatly after the biopsy (h) with the nucleus clearly visible (arrow).
the day of biopsy. Anyway, recent data have shown that embryo vitrification provides higher survival rates than conventional slow freezing [36].

One of the main issues concerning cleavage stage biopsy is the number of cells to aspirate. The choice of cell number for PGD should be the result of a balance between two aspects: an accurate and correct diagnosis of the embryo and the safeguard of its implantation potential. Two-cell analysis certainly provides a more reliable result, especially considering the problem of mosaicism. Chromosomal mosaicism is when different cells with a different chromosomal makeup coexist within the same individual who has developed from a single fertilized egg. In the past, high levels of mosaicism have been reported in cleavage stage embryos [37] and for this reason the analysis of two blastomeres or even more cells with the blastocyst stage biopsy (see the following paragraph) have been introduced. Anyway, data in the literature have shown that embryos with low-moderate chromosome mosaicism on day-3 often self-correct during their development to the blastocyst stage [38-40].

Recent studies have highlighted that the removal of 2 cells from a 8-cell embryo can result in an impaired implantation potential [41,42]. Therefore, the ESHRE PGD consortium recommends the biopsy of just one cell in PGS cycles: the aim of PGS is to improve embryo implantation potential. Two-cell analysis certainly provides a more reliable result, especially considering the problem of mosaicism. Chromosomal mosaicism is when different cells with a different chromosomal makeup coexist within the same individual who has developed from a single fertilized egg. In the past, high levels of mosaicism have been reported in cleavage stage embryos [37] and for this reason the analysis of two blastomeres or even more cells with the blastocyst stage biopsy (see the following paragraph) have been introduced. Anyway, data in the literature have shown that embryos with low-moderate chromosome mosaicism on day-3 often self-correct during their development to the blastocyst stage [38-40].

Important aspects to consider

At the blastocyst stage, a larger number of cells can be removed from the embryo with respect to cleavage stage biopsy, allowing the retrieval of a higher amount of DNA and, thus, a more accurate diagnosis. However, a blastocyst biopsied on day-5 cannot be kept in culture for more than 24h, therefore a shorter time is available for cell diagnosis and not all genetic laboratories are equipped to perform embryo diagnosis in such condition.

When the genetic results cannot be obtained within 24h from the biopsy cryopreservation should be considered as an alternative. Fortunately, different data in the literature report that blastocyst vitrification on day-5 or 6 is a successful method for cryopreservation with surprising higher survival rates than cleavage embryos in PGD programs [48,49].

Usually, two to nine cells are removed from the trophoderm without further compromising embryo development since ICM is not affected. The degree of chromosomal mosaicism detected at this stage is significantly lower compared to the one of embryos at the cleavage stage [50]. However, recent studies have indicated that mosaicism is a recurrent phenomenon also in blastocysts: TE cells may have diverged genetically from the ICM and they would not be representative of the rest of the embryo [51].

Despite the improvements obtained in culture media, blastocyst biopsy is not routinely carried out in PGD programs. Performing biopsy on day-5, the number of cycles suspended for the absence of embryos available for biopsy increases and it has been estimated that the number of cycles in which no embryo reaches the blastocyst stage are about 20% [46]. However the following consideration in support of blastocyst culture and biopsy should be taken into account: 1) a low number of embryos to process is more time and cost effective, and 2) most of the embryos that do not reach the blastocyst stage are chromosomally abnormal [52,53]. Blastocyst biopsy seems to be a better strategy as compared to cleavage stage biopsy also because different authors have reported that embryos diagnosed as aneuploid on day-3, later on day-5 have resulted in euploid blastocyst [38-40], suggesting the existence of self-correction mechanisms during the transition to blastocyst.

Finally, blastocyst biopsy can be considered as a valid alternative to embryo cleavage biopsy in FISH PGS cycles since ESHRE PGD consortium does not recommend embryo biopsy on day three for these couples [54].

3. CONCLUSION

PGD technology offers to couples at risk of transmitting a genetic disorder the chance to conceive a un-af-
fected child by the diagnosis of the genetic status of embryos and subsequent transfer of those ones free from diseases. This procedure requires an invasive manipulation named biopsy which has to be performed by well-trained embryologists since both the choice of the methodology and the way it is carried out are of crucial importance for the final outcome of the PGD/PGS program. Only when the benefit of genetic analysis overcomes the negative aspects of the biopsy, the PGS/PGD procedure can be considered worthwhile.

4. ACKNOWLEDGEMENTS

The authors thank Dr Valentina Casciani, Ph.D., for her precious help in preparing and reviewing the manuscript.

REFERENCES


[34] Roodebusch, W.E., Kim, J.G., Minhas, B.S. and Dodson, M.G. (1990) Survival and cell acquisition rates after preimplantation embryo biopsy: Use of two mechanical tech-


# ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
<th>PCR</th>
<th>Preconception genetic diagnosis</th>
<th>Preimplantation genetic diagnosis</th>
<th>Polar body</th>
<th>Preimplantation genetic screening</th>
<th>Trophectoderm cells</th>
<th>Whole-genome amplification</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMA</td>
<td>Advanced maternal age</td>
<td>PCR</td>
<td>Preconception genetic diagnosis</td>
<td>Preimplantation genetic diagnosis</td>
<td>Polar body</td>
<td>Preimplantation genetic screening</td>
<td>Trophectoderm cells</td>
<td>Whole-genome amplification</td>
</tr>
<tr>
<td>CGH</td>
<td>Comparative genomic hybridization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FISH</td>
<td>Fluorescent in situ hybridization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICM</td>
<td>Inner cell mass</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCGD</td>
<td>Pre-conception genetic diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PB</td>
<td>Polar body</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGS</td>
<td>Preimplantation genetic screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TE</td>
<td>Trophectoderm cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WGA</td>
<td>Whole-genome amplification</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>